Cardiff Oncology Inc. (CRDF)
| Bid | 2.7 |
| Market Cap | 186.93M |
| Revenue (ttm) | 684K |
| Net Income (ttm) | -45.43M |
| EPS (ttm) | -0.95 |
| PE Ratio (ttm) | -2.96 |
| Forward PE | -2.88 |
| Analyst | Buy |
| Ask | 2.85 |
| Volume | 625,354 |
| Avg. Volume (20D) | 1,215,033 |
| Open | 2.76 |
| Previous Close | 2.71 |
| Day's Range | 2.72 - 2.87 |
| 52-Week Range | 2.01 - 5.64 |
| Beta | 1.73 |
About CRDF
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevac...
Analyst Forecast
According to 3 analyst ratings, the average rating for CRDF stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 255.87% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago · seekingalpha.com
Cardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With OnvansertibCardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC, with a strong therapeutic profile and potential for high returns if approved. Onvansertib's Phase II resu...